Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.

Kitchen P, Lee KY, Clark D, Lau N, Lertsuwan J, Sawasdichai A, Satayavivad J, Oltean S, Afford S, Gaston K, Jayaraman PS.

Cancer Res. 2020 Feb 15;80(4):757-770. doi: 10.1158/0008-5472.CAN-19-0942. Epub 2019 Dec 16.

PMID:
31843982
2.

Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing.

Stevens M, Oltean S.

Front Genet. 2019 Sep 6;10:804. doi: 10.3389/fgene.2019.00804. eCollection 2019. Review.

3.

Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer.

Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ.

Elife. 2019 Sep 3;8. pii: e47678. doi: 10.7554/eLife.47678.

4.

The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds in vivo.

Stevens M, Star E, Lee M, Innes E, Li L, Bowler E, Harper S, Bates DO, Oltean S.

RNA Biol. 2019 Dec;16(12):1672-1681. doi: 10.1080/15476286.2019.1652522. Epub 2019 Aug 21.

5.

Targeting Angiogenesis in Prostate Cancer.

Melegh Z, Oltean S.

Int J Mol Sci. 2019 May 31;20(11). pii: E2676. doi: 10.3390/ijms20112676. Review.

6.

Alternative Splicing in Angiogenesis.

Bowler E, Oltean S.

Int J Mol Sci. 2019 Apr 26;20(9). pii: E2067. doi: 10.3390/ijms20092067. Review.

7.

Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis.

Stevens M, Oltean S.

Cells. 2019 Mar 28;8(4). pii: E288. doi: 10.3390/cells8040288. Review.

8.

The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy.

Stevens M, Neal CR, Craciun EC, Dronca M, Harper SJ, Oltean S.

PLoS One. 2019 Mar 13;14(3):e0212910. doi: 10.1371/journal.pone.0212910. eCollection 2019.

9.

Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease.

Kikuchi R, Stevens M, Harada K, Oltean S, Murohara T.

Adv Clin Chem. 2019;88:1-33. doi: 10.1016/bs.acc.2018.10.001. Epub 2018 Nov 16. Review.

PMID:
30612603
10.

The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.

Jumbe SL, Porazinski SR, Oltean S, Mansell JP, Vahabi B, Wilson ID, Ladomery MR.

Transl Oncol. 2019 Jan;12(1):134-142. doi: 10.1016/j.tranon.2018.09.001. Epub 2018 Oct 5.

11.

Assessment of Kidney Function in Mouse Models of Glomerular Disease.

Stevens M, Oltean S.

J Vis Exp. 2018 Jun 30;(136). doi: 10.3791/57764.

12.

Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators.

Bates DO, Beazley-Long N, Benest AV, Ye X, Ved N, Hulse RP, Barratt S, Machado MJ, Donaldson LF, Harper SJ, Peiris-Pages M, Tortonese DJ, Oltean S, Foster RR.

Compr Physiol. 2018 Jun 18;8(3):955-979. doi: 10.1002/cphy.c170015. Review.

PMID:
29978898
13.

Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease.

Stevens M, Oltean S.

Genes (Basel). 2018 Feb 15;9(2). pii: E98. doi: 10.3390/genes9020098. Review.

14.

Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury.

Stevens M, Neal CR, Salmon AHJ, Bates DO, Harper SJ, Oltean S.

Nephron. 2018;139(1):51-62. doi: 10.1159/000485664. Epub 2018 Jan 26.

15.

Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues.

Oltean S, Coward R, Collino M, Baelde H.

Biomed Res Int. 2017;2017:3146524. doi: 10.1155/2017/3146524. Epub 2017 Nov 22. No abstract available.

16.

Nuclear hyaluronidase 2 drives alternative splicing of CD44 pre-mRNA to determine profibrotic or antifibrotic cell phenotype.

Midgley AC, Oltean S, Hascall V, Woods EL, Steadman R, Phillips AO, Meran S.

Sci Signal. 2017 Nov 21;10(506). pii: eaao1822. doi: 10.1126/scisignal.aao1822.

PMID:
29162741
17.

Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis.

Barratt SL, Blythe T, Jarrett C, Ourradi K, Shelley-Fraser G, Day MJ, Qiu Y, Harper S, Maher TM, Oltean S, Hames TJ, Scotton CJ, Welsh GI, Bates DO, Millar AB.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):479-493. doi: 10.1164/rccm.201603-0568OC.

18.

The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J Jr, Kaidi A, Malik K.

Cancer Lett. 2017 Sep 10;403:74-85. doi: 10.1016/j.canlet.2017.05.027. Epub 2017 Jun 7.

19.

VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney.

Stevens M, Neal CR, Salmon AHJ, Bates DO, Harper SJ, Oltean S.

J Physiol. 2017 Oct 1;595(19):6281-6298. doi: 10.1113/JP274481. Epub 2017 Jul 3.

20.

Pharmacology of Modulators of Alternative Splicing.

Bates DO, Morris JC, Oltean S, Donaldson LF.

Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239. Review.

21.

The many faces of SRPK1.

Bullock N, Oltean S.

J Pathol. 2017 Mar;241(4):437-440. doi: 10.1002/path.4846. Epub 2017 Feb 1.

22.

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.

Mavrou A, Oltean S.

Pharmacol Res. 2016 May;107:276-281. doi: 10.1016/j.phrs.2016.03.013. Epub 2016 Mar 16.

23.

Alternative Splicing in CKD.

Stevens M, Oltean S.

J Am Soc Nephrol. 2016 Jun;27(6):1596-603. doi: 10.1681/ASN.2015080908. Epub 2016 Jan 13. Review.

24.

Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.

Bullock N, Potts J, Simpkin AJ, Koupparis A, Harper SJ, Oxley J, Oltean S.

J Clin Pathol. 2016 Feb;69(2):171-5. doi: 10.1136/jclinpath-2015-203125. Epub 2015 Oct 23.

25.

Modulators of alternative splicing as novel therapeutics in cancer.

Oltean S.

World J Clin Oncol. 2015 Oct 10;6(5):92-5. doi: 10.5306/wjco.v6.i5.92.

26.

The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.

Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG, Elliott DJ.

Oncotarget. 2015 Oct 27;6(33):34358-74. doi: 10.18632/oncotarget.6024.

27.

Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.

Bunni J, Shelley-Fraser G, Stevenson K, Oltean S, Salmon A, Harper SJ, Carter JG, Bates DO.

Am J Cancer Res. 2015 May 15;5(6):2083-9. eCollection 2015.

29.

Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.

Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, Kaura A, Arkill KP, Harris K, Symonds C, Lacey K, Wijeyaratne L, Gammons M, Wylie E, Hulse RP, Alsop C, Cope G, Damodaran G, Betteridge KB, Ramnath R, Satchell SC, Foster RR, Ballmer-Hofer K, Donaldson LF, Barratt J, Baelde HJ, Harper SJ, Bates DO, Salmon AH.

J Am Soc Nephrol. 2015 Aug;26(8):1889-904. doi: 10.1681/ASN.2014040350. Epub 2014 Dec 26.

30.

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S.

Oncogene. 2015 Aug 13;34(33):4311-9. doi: 10.1038/onc.2014.360. Epub 2014 Nov 10.

31.

Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.

Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom KJ, Salmon A, D'Silva O, Betteridge KB, Williams AC, Kerr DJ, Salmon AH, Oltean S, Midgley RS, Ladomery MR, Harper SJ, Varey AH, Bates DO.

Mol Oncol. 2015 Jan;9(1):167-78. doi: 10.1016/j.molonc.2014.07.017. Epub 2014 Aug 20.

32.

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.

Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO.

Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10.

33.

Detection of anti-IgA antibodies using the particle gel immunoassay: a rapid test for increased patient safety.

Oltean S, Epure A, Lindström K, Pardi C.

Blood Transfus. 2014 Jul;12(3):334-9. doi: 10.2450/2014.0219-13. Epub 2014 Jan 16.

34.

Hallmarks of alternative splicing in cancer.

Oltean S, Bates DO.

Oncogene. 2014 Nov 13;33(46):5311-8. doi: 10.1038/onc.2013.533. Epub 2013 Dec 16. Review.

PMID:
24336324
35.

Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation.

Oltean S, Pullerits R, Flodén A, Olausson M, Oltean M.

J Transl Med. 2013 Sep 26;11:233. doi: 10.1186/1479-5876-11-233.

36.

Detection of VEGF-A(xxx)b isoforms in human tissues.

Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S, Gammons MV, Millar AB, Salmon AH, Oltean S, Harper SJ.

PLoS One. 2013 Jul 31;8(7):e68399. doi: 10.1371/journal.pone.0068399. Print 2013.

37.

SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.

Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO.

Biochem Soc Trans. 2012 Aug;40(4):831-5. doi: 10.1042/BST20120051. Review.

PMID:
22817743
38.

VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice.

Oltean S, Neal CR, Mavrou A, Patel P, Ahad T, Alsop C, Lee T, Sison K, Qiu Y, Harper SJ, Bates DO, Salmon AH.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1026-36. doi: 10.1152/ajprenal.00410.2011. Epub 2012 Jul 18.

39.

Intraluminal polyethylene glycol stabilizes tight junctions and improves intestinal preservation in the rat.

Oltean M, Joshi M, Björkman E, Oltean S, Casselbrant A, Herlenius G, Olausson M.

Am J Transplant. 2012 Aug;12(8):2044-51. doi: 10.1111/j.1600-6143.2012.04067.x. Epub 2012 Apr 30.

40.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR.

Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.

41.

Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients.

Oltean S, Ţăţulescu D, Bondor C, Slavcovici A, Cismaru C, Lupşe M, Muntean M, Jianu C, Marcu C, Oltean M.

J Crit Care. 2012 Aug;27(4):370-5. doi: 10.1016/j.jcrc.2011.08.021. Epub 2011 Oct 26.

PMID:
22033051
42.

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA.

Mol Cancer Res. 2011 Aug;9(8):997-1007. doi: 10.1158/1541-7786.MCR-10-0490. Epub 2011 Jun 10.

43.

Clinical aspects and cytokine response in severe H1N1 influenza A virus infection.

Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, Brezoszki ES, Maxim M, Ciuce C, Mlesnite M, Gavrus RL, Laslo C, Hagau R, Petrescu M, Studnicska DM.

Crit Care. 2010;14(6):R203. doi: 10.1186/cc9324. Epub 2010 Nov 9.

44.

Overexpression of VEGF165b in podocytes reduces glomerular permeability.

Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ.

J Am Soc Nephrol. 2010 Sep;21(9):1498-509. doi: 10.1681/ASN.2009060617. Epub 2010 Aug 5.

45.

The anti-angiogenic isoforms of VEGF in health and disease.

Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1207-13. doi: 10.1042/BST0371207.

46.

Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo.

Oltean S, Febbo PG, Garcia-Blanco MA.

Clin Exp Metastasis. 2008;25(6):611-9. doi: 10.1007/s10585-008-9186-y. Epub 2008 Jun 4.

47.
48.

Translational regulation of human methionine synthase by upstream open reading frames.

Col B, Oltean S, Banerjee R.

Biochim Biophys Acta. 2007 Sep-Oct;1769(9-10):532-40. Epub 2007 Jul 6.

49.

Imaging the alternative silencing of FGFR2 exon IIIb in vivo.

Bonano VI, Oltean S, Brazas RM, Garcia-Blanco MA.

RNA. 2006 Dec;12(12):2073-9. Epub 2006 Oct 26.

50.

Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.

Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, Garcia-Blanco MA.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14116-21. Epub 2006 Sep 8.

Supplemental Content

Loading ...
Support Center